Epidemiology of SARS-CoV-2 infection and COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new β‑Coronavirus that was first detected in 2019 in Wuhan, China. In the ensuing months it has been transmitted worldwide. Here the authors present the current knowledge on the epidemiology of this virus. SARS-CoV‑2 replicates mainly in the upper and lower respiratory tract and is primarily transmitted by droplets from asymptomatic and symptomatic infected subjects. The estimate for the basic reproduction number (R) is currently between 2 and 3, while the incubation period is 6 (median, range 2-14) days. Although most infections are uncomplicated, 5-10% of cases develop pneumonia, which can lead to hospitalization, respiratory failure and multiorgan failure. Risk factors for a complicated disease course include age, hypertension, chronic cardiovascular and pulmonary disease and immunodeficiency. The overall case fatality rate is 1.4%, with the rate rising in the sixth decade of life. Nosocomial and infections in medical personnel have been reported. Drastic reductions in social contact have been implemented in many countries with outbreaks of SARS-CoV‑2, leading to rapid reductions in R. Which of the measures have been effective is still unknown.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Der Internist - 61(2020), 8 vom: 16. Aug., Seite 782-788 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Epidemiologie von SARS-CoV-2-Infektion und COVID-19 |
|---|
| Beteiligte Personen: |
Salzberger, B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
“Coronavirus disease 2019” (COVID-19)/epidemiology |
|---|
| Anmerkungen: |
Date Completed 05.08.2020 Date Revised 17.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00108-020-00834-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311274390 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311274390 | ||
| 003 | DE-627 | ||
| 005 | 20231225141913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00108-020-00834-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311274390 | ||
| 035 | |a (NLM)32548652 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Salzberger, B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epidemiology of SARS-CoV-2 infection and COVID-19 |
| 246 | 3 | 3 | |a Epidemiologie von SARS-CoV-2-Infektion und COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.08.2020 | ||
| 500 | |a Date Revised 17.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new β‑Coronavirus that was first detected in 2019 in Wuhan, China. In the ensuing months it has been transmitted worldwide. Here the authors present the current knowledge on the epidemiology of this virus. SARS-CoV‑2 replicates mainly in the upper and lower respiratory tract and is primarily transmitted by droplets from asymptomatic and symptomatic infected subjects. The estimate for the basic reproduction number (R) is currently between 2 and 3, while the incubation period is 6 (median, range 2-14) days. Although most infections are uncomplicated, 5-10% of cases develop pneumonia, which can lead to hospitalization, respiratory failure and multiorgan failure. Risk factors for a complicated disease course include age, hypertension, chronic cardiovascular and pulmonary disease and immunodeficiency. The overall case fatality rate is 1.4%, with the rate rising in the sixth decade of life. Nosocomial and infections in medical personnel have been reported. Drastic reductions in social contact have been implemented in many countries with outbreaks of SARS-CoV‑2, leading to rapid reductions in R. Which of the measures have been effective is still unknown | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Basic reproduction number | |
| 650 | 4 | |a Incubation period | |
| 650 | 4 | |a Mortality rate | |
| 650 | 4 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| 650 | 4 | |a “Coronavirus disease 2019” (COVID-19)/epidemiology | |
| 700 | 1 | |a Buder, F |e verfasserin |4 aut | |
| 700 | 1 | |a Lampl, B |e verfasserin |4 aut | |
| 700 | 1 | |a Ehrenstein, B |e verfasserin |4 aut | |
| 700 | 1 | |a Hitzenbichler, F |e verfasserin |4 aut | |
| 700 | 1 | |a Hanses, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Internist |d 1960 |g 61(2020), 8 vom: 16. Aug., Seite 782-788 |w (DE-627)NLM000030767 |x 1432-1289 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2020 |g number:8 |g day:16 |g month:08 |g pages:782-788 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00108-020-00834-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2020 |e 8 |b 16 |c 08 |h 782-788 | ||